Second-Line Chemotherapy vs an Androgen Receptor–Targeted Agent for Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Real-World Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Second-Line Chemotherapy Versus an Alternative Androgen Receptor-Targeted Agent (ARTA) Following Early Progression on a First-Line ARTA in a US Community Oncology Setting
Urol. Oncol 2018 Sep 07;[EPub Ahead of Print], Wk Oh, WY Cheng, R Miao, et alAdvanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.